From d06f4cb6531e71db06c0c58f20a9e4a1425ab81f Mon Sep 17 00:00:00 2001 From: Teleo Agents Date: Sun, 26 Apr 2026 04:22:31 +0000 Subject: [PATCH] vida: extract claims from 2026-04-08-23andme-nature-glp1-pharmacogenomics - Source: inbox/queue/2026-04-08-23andme-nature-glp1-pharmacogenomics.md - Domain: health - Claims: 1, Entities: 1 - Enrichments: 3 - Extracted by: pipeline ingest (OpenRouter anthropic/claude-sonnet-4.5) Pentagon-Agent: Vida --- ...ts-predict-weight-loss-and-side-effects.md | 19 ++++++++++++ ...r-outcomes-despite-inferior-weight-loss.md | 20 ++++++------- entities/health/23andme-research-institute.md | 29 +++++++++++++++++++ ...08-23andme-nature-glp1-pharmacogenomics.md | 5 +++- 4 files changed, 62 insertions(+), 11 deletions(-) create mode 100644 domains/health/glp1-response-variability-partially-genetically-determined-glp1r-gipr-variants-predict-weight-loss-and-side-effects.md create mode 100644 entities/health/23andme-research-institute.md rename inbox/{queue => archive/health}/2026-04-08-23andme-nature-glp1-pharmacogenomics.md (98%) diff --git a/domains/health/glp1-response-variability-partially-genetically-determined-glp1r-gipr-variants-predict-weight-loss-and-side-effects.md b/domains/health/glp1-response-variability-partially-genetically-determined-glp1r-gipr-variants-predict-weight-loss-and-side-effects.md new file mode 100644 index 000000000..5e542bcc1 --- /dev/null +++ b/domains/health/glp1-response-variability-partially-genetically-determined-glp1r-gipr-variants-predict-weight-loss-and-side-effects.md @@ -0,0 +1,19 @@ +--- +type: claim +domain: health +description: First large-scale pharmacogenomics evidence for GLP-1 response heterogeneity enabling genetic stratification to optimize drug selection and reduce treatment discontinuation +confidence: experimental +source: 23andMe Research Institute, Nature 2026, n=27,885 +created: 2026-04-26 +title: "GLP-1 receptor agonist weight loss and side effects are partially genetically determined with GLP1R and GIPR variants predicting 6-20% weight loss range and up to 14.8-fold variation in tirzepatide-specific vomiting risk" +agent: vida +sourced_from: health/2026-04-08-23andme-nature-glp1-pharmacogenomics.md +scope: causal +sourcer: 23andMe Research Institute +supports: ["glp-1-access-structure-inverts-need-creating-equity-paradox"] +related: ["glp1-long-term-persistence-ceiling-14-percent-year-two", "semaglutide-achieves-47-percent-one-year-persistence-versus-19-percent-for-liraglutide-showing-drug-specific-adherence-variation-of-2-5x", "glp-1-access-structure-inverts-need-creating-equity-paradox", "semaglutide-outperforms-tirzepatide-cardiovascular-outcomes-despite-inferior-weight-loss-suggesting-glp1r-specific-cardiac-mechanism", "semaglutide-outperforms-tirzepatide-cardiovascular-outcomes-despite-inferior-weight-loss", "glp1-receptor-agonists-provide-cardiovascular-benefits-through-weight-independent-mechanisms"] +--- + +# GLP-1 receptor agonist weight loss and side effects are partially genetically determined with GLP1R and GIPR variants predicting 6-20% weight loss range and up to 14.8-fold variation in tirzepatide-specific vomiting risk + +A genome-wide association study of 27,885 individuals using semaglutide or tirzepatide identified genetic variants that explain significant portions of treatment response variability. A missense variant in GLP1R was associated with an additional -0.76 kg weight loss per copy of the effect allele, contributing to a predicted weight loss range of 6-20% of starting body weight across participants—a 3.3-fold variation. More clinically actionable: variants in GLP1R and GIPR predict nausea/vomiting risk, with the GIPR association being drug-specific to tirzepatide (not semaglutide). Individuals homozygous for risk alleles at both loci showed 14.8-fold increased odds of tirzepatide-mediated vomiting, with predicted nausea/vomiting risk ranging from 5% to 78%—a 15-fold variation. The drug-specificity of the GIPR finding is mechanistically coherent (tirzepatide is a dual GLP-1/GIP agonist while semaglutide targets only GLP-1) and immediately actionable: patients with GIPR risk alleles could be preferentially prescribed semaglutide to reduce discontinuation risk. The findings were validated in an independent EHR dataset. 23andMe launched this as a commercial genetic test through their Total Health subscription service, making it the first consumer-available pharmacogenomics test for GLP-1 response. However, the study population (23andMe users who self-reported GLP-1 use) skews white, educated, and affluent, limiting generalizability to populations with highest obesity burden. diff --git a/domains/health/semaglutide-outperforms-tirzepatide-cardiovascular-outcomes-despite-inferior-weight-loss.md b/domains/health/semaglutide-outperforms-tirzepatide-cardiovascular-outcomes-despite-inferior-weight-loss.md index b5937fcb1..9c4d77e05 100644 --- a/domains/health/semaglutide-outperforms-tirzepatide-cardiovascular-outcomes-despite-inferior-weight-loss.md +++ b/domains/health/semaglutide-outperforms-tirzepatide-cardiovascular-outcomes-despite-inferior-weight-loss.md @@ -10,17 +10,17 @@ agent: vida scope: causal sourcer: STEER investigators related_claims: ["[[GLP-1 receptor agonists are the largest therapeutic category launch in pharmaceutical history but their chronic use model makes the net cost impact inflationary through 2035]]"] -related: -- Real-world semaglutide use in ASCVD patients shows 43-57% MACE reduction compared to 20% in SELECT trial because treated populations have better adherence and access creating positive selection bias -reweave_edges: -- Real-world semaglutide use in ASCVD patients shows 43-57% MACE reduction compared to 20% in SELECT trial because treated populations have better adherence and access creating positive selection bias|related|2026-04-09 -- Semaglutide achieves 29-43 percent lower major adverse cardiovascular event rates compared to tirzepatide despite tirzepatide's superior weight loss suggesting a GLP-1 receptor-specific cardioprotective mechanism independent of weight reduction|supports|2026-04-10 -- GLP-1 receptor agonists provide cardiovascular benefits through weight-independent mechanisms including direct cardiac GLP-1R signaling which explains why semaglutide outperforms tirzepatide in MACE reduction despite inferior weight loss|supports|2026-04-12 -supports: -- Semaglutide achieves 29-43 percent lower major adverse cardiovascular event rates compared to tirzepatide despite tirzepatide's superior weight loss suggesting a GLP-1 receptor-specific cardioprotective mechanism independent of weight reduction -- GLP-1 receptor agonists provide cardiovascular benefits through weight-independent mechanisms including direct cardiac GLP-1R signaling which explains why semaglutide outperforms tirzepatide in MACE reduction despite inferior weight loss +related: ["Real-world semaglutide use in ASCVD patients shows 43-57% MACE reduction compared to 20% in SELECT trial because treated populations have better adherence and access creating positive selection bias", "semaglutide-outperforms-tirzepatide-cardiovascular-outcomes-despite-inferior-weight-loss", "semaglutide-outperforms-tirzepatide-cardiovascular-outcomes-despite-inferior-weight-loss-suggesting-glp1r-specific-cardiac-mechanism", "glp1-receptor-agonists-provide-cardiovascular-benefits-through-weight-independent-mechanisms", "real-world-semaglutide-shows-stronger-mace-reduction-than-select-trial", "semaglutide-cardiovascular-benefit-is-67-percent-independent-of-weight-loss-with-inflammation-as-primary-mediator"] +reweave_edges: ["Real-world semaglutide use in ASCVD patients shows 43-57% MACE reduction compared to 20% in SELECT trial because treated populations have better adherence and access creating positive selection bias|related|2026-04-09", "Semaglutide achieves 29-43 percent lower major adverse cardiovascular event rates compared to tirzepatide despite tirzepatide's superior weight loss suggesting a GLP-1 receptor-specific cardioprotective mechanism independent of weight reduction|supports|2026-04-10", "GLP-1 receptor agonists provide cardiovascular benefits through weight-independent mechanisms including direct cardiac GLP-1R signaling which explains why semaglutide outperforms tirzepatide in MACE reduction despite inferior weight loss|supports|2026-04-12"] +supports: ["Semaglutide achieves 29-43 percent lower major adverse cardiovascular event rates compared to tirzepatide despite tirzepatide's superior weight loss suggesting a GLP-1 receptor-specific cardioprotective mechanism independent of weight reduction", "GLP-1 receptor agonists provide cardiovascular benefits through weight-independent mechanisms including direct cardiac GLP-1R signaling which explains why semaglutide outperforms tirzepatide in MACE reduction despite inferior weight loss"] --- # Semaglutide produces superior cardiovascular outcomes compared to tirzepatide despite achieving less weight loss because GLP-1 receptor-specific cardiac mechanisms operate independently of weight reduction -The STEER study compared semaglutide to tirzepatide in 10,625 matched patients with overweight/obesity and established ASCVD without diabetes. Semaglutide demonstrated 29% lower risk of revised 3-point MACE and 22% lower risk of revised 5-point MACE compared to tirzepatide, with per-protocol analysis showing even stronger effects (43% and 57% reductions). This finding is counterintuitive because tirzepatide consistently achieves greater weight loss than semaglutide across trials. The divergence suggests that GLP-1 receptor activation produces cardiovascular benefits through mechanisms beyond weight reduction alone. GLP-1 receptors are directly expressed in cardiac tissue, while tirzepatide's dual GIP/GLP-1 receptor agonism may produce different cardiac effects. This challenges the prevailing model that weight loss is the primary mediator of GLP-1 cardiovascular benefit and suggests receptor-specific cardiac mechanisms matter independently. The finding is limited to established ASCVD patients (highest-risk subgroup) and requires replication, but represents a genuine mechanistic surprise. \ No newline at end of file +The STEER study compared semaglutide to tirzepatide in 10,625 matched patients with overweight/obesity and established ASCVD without diabetes. Semaglutide demonstrated 29% lower risk of revised 3-point MACE and 22% lower risk of revised 5-point MACE compared to tirzepatide, with per-protocol analysis showing even stronger effects (43% and 57% reductions). This finding is counterintuitive because tirzepatide consistently achieves greater weight loss than semaglutide across trials. The divergence suggests that GLP-1 receptor activation produces cardiovascular benefits through mechanisms beyond weight reduction alone. GLP-1 receptors are directly expressed in cardiac tissue, while tirzepatide's dual GIP/GLP-1 receptor agonism may produce different cardiac effects. This challenges the prevailing model that weight loss is the primary mediator of GLP-1 cardiovascular benefit and suggests receptor-specific cardiac mechanisms matter independently. The finding is limited to established ASCVD patients (highest-risk subgroup) and requires replication, but represents a genuine mechanistic surprise. + +## Extending Evidence + +**Source:** 23andMe Research Institute, Nature 2026 + +The GIPR genetic variant predicts tirzepatide-specific side effects but not semaglutide side effects, providing a mechanism-based rationale for drug selection beyond just cardiovascular vs. weight loss outcomes. Patients with GIPR risk alleles might benefit more from semaglutide not only for cardiovascular reasons but also to avoid treatment discontinuation due to intolerable side effects. diff --git a/entities/health/23andme-research-institute.md b/entities/health/23andme-research-institute.md new file mode 100644 index 000000000..9413cd51f --- /dev/null +++ b/entities/health/23andme-research-institute.md @@ -0,0 +1,29 @@ +# 23andMe Research Institute + +**Type:** Research organization (commercial genomics company research arm) +**Founded:** Part of 23andMe, Inc. (founded 2006) +**Focus:** Population genomics, pharmacogenomics, genetic epidemiology +**Status:** Active + +## Overview + +The 23andMe Research Institute is the research division of 23andMe, Inc., conducting large-scale genetic studies using the company's consumer genomics database. The institute leverages self-reported health data from millions of 23andMe customers combined with genotype data to conduct genome-wide association studies (GWAS) and pharmacogenomics research. + +## Key Research + +### GLP-1 Pharmacogenomics (2026) + +Published the largest pharmacogenomics study of GLP-1 receptor agonist response to date, analyzing 27,885 individuals who used semaglutide or tirzepatide. The study identified genetic variants in GLP1R and GIPR that predict both weight loss efficacy (6-20% range) and side effect risk (5-78% nausea/vomiting risk range). Notably discovered that GIPR variants predict tirzepatide-specific side effects but not semaglutide side effects, enabling genetic-guided drug selection. + +## Commercial Translation + +23andMe launched a "GLP-1 Medications Weight Loss and Nausea" genetic report for Total Health subscribers based on this research, making it the first consumer-available pharmacogenomics test for GLP-1 response. The test is available only through 23andMe's subscription service (not covered by insurance). + +## Research Model + +The institute operates at the intersection of consumer genomics and clinical research, using self-reported outcomes data (potential reporting bias) from a non-representative population (skews white, educated, affluent). Findings are typically validated in independent electronic health record datasets. + +## Timeline + +- **2026-04-08** — Published GLP-1 pharmacogenomics study in Nature (n=27,885), identifying GLP1R and GIPR variants predicting weight loss and side effects +- **2026-04-08** — Launched commercial GLP-1 genetic testing through Total Health subscription service \ No newline at end of file diff --git a/inbox/queue/2026-04-08-23andme-nature-glp1-pharmacogenomics.md b/inbox/archive/health/2026-04-08-23andme-nature-glp1-pharmacogenomics.md similarity index 98% rename from inbox/queue/2026-04-08-23andme-nature-glp1-pharmacogenomics.md rename to inbox/archive/health/2026-04-08-23andme-nature-glp1-pharmacogenomics.md index 9b1f8cf86..422ba11dd 100644 --- a/inbox/queue/2026-04-08-23andme-nature-glp1-pharmacogenomics.md +++ b/inbox/archive/health/2026-04-08-23andme-nature-glp1-pharmacogenomics.md @@ -7,9 +7,12 @@ date: 2026-04-08 domain: health secondary_domains: [] format: peer-reviewed study -status: unprocessed +status: processed +processed_by: vida +processed_date: 2026-04-26 priority: high tags: [glp-1, pharmacogenomics, precision-medicine, semaglutide, tirzepatide, GLP1R, GIPR, weight-loss, obesity, GWAS] +extraction_model: "anthropic/claude-sonnet-4.5" --- ## Content -- 2.45.2